Equity Profile

ACLX

Arcellx, Inc.

Health CareBiotechnology$6.7B

May7Thu

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EDT

Company Snapshot

Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be watching closely to see if the company can narrow its losses.

$-1.02

Revenue

Revenue growth is essential for assessing the company's market traction and potential for future profitability.

$6M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACLX Q1-2026 Earnings Preview

Context

Company Snapshot

Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. With a market cap of $7 billion, it operates in the health care sector, where advancements in treatment options are critical for patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-36.35%

Avg Stock Reaction

+2.14%

Last Quarter Recap

In Q4-2025, Arcellx reported a significant earnings miss with an EPS of $-4.07, far below expectations. The stock had a slight positive reaction the following day, indicating some investor optimism despite the disappointing results.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are generally cautious ahead of the earnings report, expecting continued losses but hoping for signs of revenue growth. The consensus EPS and revenue figures suggest that investors are looking for improvements from previous quarters.

Bull Case

If Arcellx can show a narrower loss than expected and better-than-consensus revenue, it could signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company reports worse-than-expected losses and stagnant revenue, it could raise concerns about its long-term viability and lead to a significant sell-off.

Key Metrics to Watch

EPS

$-1.02

Earnings per share is a key indicator of profitability, and investors will be watching closely to see if the company can narrow its losses.

Revenue

$6M

Revenue growth is essential for assessing the company's market traction and potential for future profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Arcellx report an EPS closer to the consensus estimate of $-1.02?

A narrower loss could indicate operational improvements and boost investor sentiment.

How does the revenue of $6M compare to previous quarters?

Revenue growth is crucial for demonstrating the company's market traction and potential for future profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth driven by new product developments and partnerships.

Supporting Evidence

The average revenue estimate of $6M may not fully account for recent advancements in their pipeline.

Historical trends show that Arcellx has surprised positively in the past, indicating potential for better-than-expected results.

Key Risk

If revenue comes in above $8M, it could significantly shift the narrative around the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved financial performance against the backdrop of previous losses.

Bull Confirmed If

If EPS is reported at $-0.95 or better and revenue exceeds $6M, it would confirm a positive outlook.

Bear Confirmed If

If EPS worsens to $-1.11 or worse and revenue falls below $4M, it would confirm ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±0.52%

Historical Avg

±2.3%

Pricing cheap

The options market is pricing in a relatively small move, suggesting that investors are uncertain about significant changes in stock price following the earnings report.

Options are pricing ±0.5% while ACLX has averaged ±2.3% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcellx beats expectations, history suggests the stock could rise by an average of +2.88%, confirming a positive shift in investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

If the company misses expectations, history suggests an average decline of -1.40%, which could raise concerns about its future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements or partnerships that could drive revenue.
2Management's commentary on cost management strategies and plans to reduce losses.
3Insights into market demand for Arcellx's therapies and any competitive developments.
4Guidance on future revenue expectations and operational milestones.
5Any changes in management's outlook based on recent performance metrics.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

BSMReported

Black Stone Minerals, L.P.

RecapView

May4

FOLDAMC

Company Snapshot

Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be watching closely to see if the company can narrow its losses.

$-1.02

Revenue

Revenue growth is essential for assessing the company's market traction and potential for future profitability.

$6M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACLX Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-36.35%

Avg Stock Reaction

+2.14%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Arcellx can show a narrower loss than expected and better-than-consensus revenue, it could signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company reports worse-than-expected losses and stagnant revenue, it could raise concerns about its long-term viability and lead to a significant sell-off.

Key Metrics to Watch

EPS

$-1.02

Earnings per share is a key indicator of profitability, and investors will be watching closely to see if the company can narrow its losses.

Revenue

$6M

Revenue growth is essential for assessing the company's market traction and potential for future profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Arcellx report an EPS closer to the consensus estimate of $-1.02?

A narrower loss could indicate operational improvements and boost investor sentiment.

How does the revenue of $6M compare to previous quarters?

Revenue growth is crucial for demonstrating the company's market traction and potential for future profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth driven by new product developments and partnerships.

Supporting Evidence

The average revenue estimate of $6M may not fully account for recent advancements in their pipeline.

Historical trends show that Arcellx has surprised positively in the past, indicating potential for better-than-expected results.

Key Risk

If revenue comes in above $8M, it could significantly shift the narrative around the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved financial performance against the backdrop of previous losses.

Bull Confirmed If

If EPS is reported at $-0.95 or better and revenue exceeds $6M, it would confirm a positive outlook.

Bear Confirmed If

If EPS worsens to $-1.11 or worse and revenue falls below $4M, it would confirm ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±0.52%

Historical Avg

±2.3%

Pricing cheap

The options market is pricing in a relatively small move, suggesting that investors are uncertain about significant changes in stock price following the earnings report.

Options are pricing ±0.5% while ACLX has averaged ±2.3% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcellx beats expectations, history suggests the stock could rise by an average of +2.88%, confirming a positive shift in investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

If the company misses expectations, history suggests an average decline of -1.40%, which could raise concerns about its future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements or partnerships that could drive revenue.
2Management's commentary on cost management strategies and plans to reduce losses.
3Insights into market demand for Arcellx's therapies and any competitive developments.
4Guidance on future revenue expectations and operational milestones.
5Any changes in management's outlook based on recent performance metrics.